Knowing the number of deaths, I actually feel more assured that LL may be able to hit their primary endpoint. It either works, or it doesn't. Even if you think there's only a 25% chance of them getting any kind of approval for Covid, the payout will be better than 4 to 1 (depending what you bought in for).I think this is the last straw for me, at least at this price. Seriously considering selling. I was not in early, so this will just be break even. Maybe I’ll hop back in if it drops, not sure. I also can’t handle/trust management.
Right. Pot odds for a lot of us are outstanding right now.Knowing the number of deaths, I actually feel more assured that LL may be able to hit their primary endpoint. It either works, or it doesn't. Even if you think there's only a 25% chance of them getting any kind of approval for Covid, the payout will be better than 4 to 1 (depending what you bought in for).
# of deaths, the fda early use thingie and the insurance code is way more than enough for meKnowing the number of deaths, I actually feel more assured that LL may be able to hit their primary endpoint. It either works, or it doesn't. Even if you think there's only a 25% chance of them getting any kind of approval for Covid, the payout will be better than 4 to 1 (depending what you bought in for).
And the FDA has stopped several trials at the midway peak. They recommended this one to continue without any modifications. Why punt when you're a couple weeks away from results.# of deaths, the fda early use thingie and the insurance code is way more than enough for me
Lol for sure. But people play their hands differently.And the FDA has stopped several trials at the midway peak. They recommended this one to continue without any modifications. Why punt when you're a couple weeks away from results.
What would bother you more? Staying long and watching the stock go back down to $1.50, or selling now and watching the stock moon to $50.
Can those smarter than me back up the math claims of these tweets?Take it for what it's worth given the source (I haven't went and actually looked at the studies), but here's some info on mortality: tweet 1 | tweet 2. Just presenting info to be considered, not trying to make anyone grumpy - no position at this point.
My personal stance here is I will forever be grateful to @chet for the call here, made a bunch of loot - but I have come to believe, in general, management matters. I also believe mortality as the primary endpoint makes this tough and maybe not great risk/reward going in to unblinding. If the data isn't great with the company is already valued at ~$3.5 billion dollars there is a lot of room to fall. I think we can get lost in the stock price sometimes and forget what it extrapolates to. For example, $HGEN has an $850M market cap a 4x difference (and I believe a generally higher chance of getting approval given how the studies have been setup. See: importance of management).
I don't know about the math but look at that twitter account's history. He tweets every day about CytoDyn only in a negative light. Seems like an obvious short interest.Can those smarter than me back up the math claims of these tweets?
That twitter account kgromax is unreadable. I'm all for consenting opinions, I have them myself but that guy has a clear agenda against Cytodyn. Every day several times a day, he is posting negatively about Cytodyn.I don't know about the math but look at that twitter account's history. He tweets every day about CytoDyn only in a negative light. Seems like an obvious short interest.
I dismiss anyone that doesn't have any balance at all. It goes for pumpers and bashers. Kgromax is 100% negative on Cytodyn, can't be trustedSure but this time has numbers. Sounds legit-ish. Worth a verification if you have any money.
The shorts have bad intentions, but they CYDY hasn't delivered anything aside from the stock price. Uplisting. HIV. Mexico. UK. Philippines. NP has LIED whether EUA was filed.
I don't dismiss those guys entirely.
That's where I have my sell order in. I think it goes down from there. I will buy back in at 4.5-4.6Schwab showing 5.15, not the worst...
Well, it just changed to 5.06That's where I have my sell order in. I think it goes down from there. I will buy back in at 4.5-4.6
If it doesn't get to that level, I can't say I will regret being completely out, even at a loss.
Oh well. I'm not chasing. Guess I'm along for the ride.Well, it just changed to 5.06
Yep. We've been through this before.Oh well. I'm not chasing. Guess I'm along for the ride.
After sleeping on it I decided the same thing. Hanging out again for the roller coaster.Oh well. I'm not chasing. Guess I'm along for the ride.
Hellostill own 6500 shares at 2.26. this was a buy & hold so never sold although it's been a wild ride. anyone else with original investment still in place?
regardless we all had a chance to get out & make a bunch of money based on your initial tip.Hello
And yes to your question
Yep, in just over two months, any sales I make of my original 1000 shares will be long term gains.still own 6500 shares at 2.26. this was a buy & hold so never sold although it's been a wild ride. anyone else with original investment still in place?
It has had good support at $5 for the last couple of weeks. Between Dec 21 and Dec 31, 6 out of 8 trading days had a low between $4.90 and $5.01.Seems to have support at 5.
CytoDyn Update Reveals Q1 Sales Pipeline, Philippine EUA, NASDAQ Uplisting, & High Likelihood of Approval
https://emerginggrowth.com/cytodyn-update-reveals-q1-sales-pipeline-philippine-eua-nasdaq-uplisting-high-likelihood-of-approval/
Yeah. Not sure what conference call they listened to, but that's the one NP should have conducted.Well now I’m excited again
Article was written by Chris Long, not Chris ShortYeah. Not sure what conference call they listened to, but that's the one NP should have conducted.
For a lot of longs and shorts, everything is spin. Obviously, longs believe in the stock and shorts disbelieve in the stock. But there is dishonesty in the 100% slanted perspective both camps put forth.So funny how people perceive the same event.